JP2025505141A5 - - Google Patents

Info

Publication number
JP2025505141A5
JP2025505141A5 JP2024545807A JP2024545807A JP2025505141A5 JP 2025505141 A5 JP2025505141 A5 JP 2025505141A5 JP 2024545807 A JP2024545807 A JP 2024545807A JP 2024545807 A JP2024545807 A JP 2024545807A JP 2025505141 A5 JP2025505141 A5 JP 2025505141A5
Authority
JP
Japan
Prior art keywords
crystal morphology
morphology according
xrpd pattern
radiation
further characterized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012251 external-priority patent/WO2023150249A1/en
Publication of JP2025505141A publication Critical patent/JP2025505141A/ja
Publication of JP2025505141A5 publication Critical patent/JP2025505141A5/ja
Pending legal-status Critical Current

Links

JP2024545807A 2022-02-04 2023-02-03 Ｍｃｌ－１阻害剤の結晶形態 Pending JP2025505141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306776P 2022-02-04 2022-02-04
US63/306,776 2022-02-04
PCT/US2023/012251 WO2023150249A1 (en) 2022-02-04 2023-02-03 Crystalline forms of an mcl-1 inhibitor

Publications (2)

Publication Number Publication Date
JP2025505141A JP2025505141A (ja) 2025-02-21
JP2025505141A5 true JP2025505141A5 (enExample) 2026-02-06

Family

ID=85570021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545807A Pending JP2025505141A (ja) 2022-02-04 2023-02-03 Ｍｃｌ－１阻害剤の結晶形態

Country Status (7)

Country Link
US (1) US20250115622A1 (enExample)
EP (1) EP4472984A1 (enExample)
JP (1) JP2025505141A (enExample)
AU (1) AU2023216691A1 (enExample)
CA (1) CA3246092A1 (enExample)
MX (1) MX2024009448A (enExample)
WO (1) WO2023150249A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化

Similar Documents

Publication Publication Date Title
JP2025176008A5 (enExample)
JP2007521340A5 (enExample)
US20140066466A1 (en) Necroptosis Inhibitors and Methods of Use Therefor
WO2020052627A1 (zh) 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途
RU2012138892A (ru) СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА
CN102675380A (zh) 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
JP2006528973A5 (enExample)
JP3476420B2 (ja) 結晶性１−メチルカルバペネム化合物
JP2022511029A5 (enExample)
JP7257328B2 (ja) ベンゾフラン誘導体遊離塩基の結晶およびその製造方法
JP6937322B2 (ja) 置換ピペリジン化合物の塩
JP2020536893A5 (enExample)
JP2023027066A5 (enExample)
CN119744262A (zh) 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途
JP2025505141A5 (enExample)
JP2022534788A5 (enExample)
US11286247B2 (en) Acryloyl-containing nuclear transport regulators and uses thereof
JP2025511331A5 (enExample)
JP2023530786A5 (enExample)
JP2024001040A5 (enExample)
JP2024509276A5 (enExample)
JP2025513774A5 (enExample)
JP2025505142A5 (enExample)
CN101506169A (zh) 马来酸氟吡汀的药学可接受的盐及多晶型物
JP2022548689A5 (enExample)